Ipinzan

Metformin Hydrochloride / Vildagliptin, the active ingredient in Ipinzan, is a Biguanide / DPP-4 inhibitor presented as an oral tablet formulation for oral use. It is indicated for the management of type 2 diabetes mellitus in adults, often as part of combination therapy when diet, exercise, and monotherapy are insufficient.

GNH USA supplies Ipinzan as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Ipinzan is an oral antidiabetic combination that targets hyperglycaemia in type 2 diabetes mellitus.

- Type 2 diabetes mellitus: improves glycaemic control as part of combination therapy. - Inadequate control on metformin alone: adds DPP‑4 inhibition to further lower HbA1c. - Adjunct to diet and exercise: helps achieve target blood‑glucose levels when lifestyle measures alone are insufficient.

Common side effects of Ipinzan are generally mild and related to gastrointestinal tolerance or transient discomfort.

Common Side Effects: - Nausea: mild to moderate feeling of sickness. - Diarrhoea: loose stools occurring intermittently. - Abdominal discomfort: cramping or pain in the stomach area. - Headache: mild to moderate head pain. - Dizziness: sensation of light‑headedness. - Upper respiratory tract infection: mild cold‑like symptoms.

Serious or Rare Side Effects: - Lactic acidosis: rare but life‑threatening metabolic disturbance. - Severe hypoglycaemia: especially when combined with other glucose‑lowering agents. - Pancreatitis: inflammation of the pancreas presenting with abdominal pain. - Severe skin reactions: such as Stevens‑Johnson syndrome. - Hepatic dysfunction: abnormal liver enzymes or liver injury. - Renal impairment: worsening kidney function, particularly in susceptible patients.

Before initiating Ipinzan, clinicians should evaluate patient‑specific factors and monitor for potential complications.

- Renal function assessment: evaluate renal function before starting and periodically thereafter. - Lactic acidosis risk: avoid in patients with severe renal impairment or conditions predisposing to hypoxia. - Hepatic disease: use with caution in patients with existing liver dysfunction. - Pregnancy and lactation: safety not established; weigh benefits against potential risks. - Drug interactions: review concomitant medications for possible interactions. - Store at ambient temperature: keep below 25°C, protect from moisture and light.

Ipinzan may interact with several medicines, requiring careful assessment.

Major Interactions (Avoid): - Concomitant use with potent CYP450 inhibitors: may increase vildagliptin plasma concentrations. - Combination with other hypoglycaemic agents: heightened risk of severe hypoglycaemia. - Iodinated contrast media in patients on metformin: risk of lactic acidosis; discontinue metformin before and after the procedure.

Moderate Interactions (Monitor Closely): - Diuretics and ACE inhibitors: may affect renal function; monitor renal parameters. - Alcohol intake: can potentiate metformin‑related lactic acidosis. - Beta‑blockers: may mask hypoglycaemia symptoms; observe glucose levels closely.